Assessment of the activity of tigecycline against gram-positive and gram-negative organisms collected from Italy between 2012 and 2014, as part of the tigecycline evaluation and surveillance trial (T.E.S.T.)

Pharmaceuticals

Volumn 9, Issue 4, 2016, Pages

  Stefani, Stefania ^a   Dowzicky, Michael J ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b PFIZER INC   (United States)

Author keywords

Antimicrobial resistance; Gram negative; Gram positive; Italy; Multidrug resistance; Surveillance; Tigecycline

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAMASE; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; ITALY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN;

EID: 85000363150     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph9040074     Document Type: Article

References (39)

1. European Center for Disease Prevention and Control. Antimicrobial Resistance Surveillance in Europe 2014, Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net), ECDC: Stockholm, Sweden, 2015.
2. Hulscher, M.E., van der Meer, J.W., Grol, R.P. Antibiotic use: How to improve it? Int. J. Med. Microbiol. 2010, 300, 351-356. [CrossRef] [PubMed]
3. Gualano, M.R., Gili, R., Scaioli, G., Bert, F., Siliquini, R. General population’s knowledge and attitudes about antibiotics: A systematic review and meta-analysis. Pharmacoepidemiol. Drug Saf. 2015, 24, 2-10. [CrossRef] [PubMed]
4. Campanile, F., Bongiorno, D., Perez, M., Mongelli, G., Sesssa, L., Benvenuto, S., Gona, F., AMCLI-S. aureus Survey Participants, Varaldo, P.E., Stefani, S. Epidemiology of Staphylococcus aureus in Italy: First nationwide survey, 2012. J. Glob. Antimicrob. Resist. 2015, 3, 247-254. [CrossRef] [PubMed]
5. Giani, T., Pini, B., Arena, F., Conte, V., Bracco, S., Migliavacca, R., Pantosti, A., Pagani, L., Luzzaro, F., et al. Epidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: Results of the first countrywide survey, 15 May to 30 June 2011. Euro Surveill. 2013, 18, 1-9.
6. Pfizer Inc. (Wyeth Pharmaceuticals). Tygacil® Package Insert, Pfizer Inc.: Philadelphia, PA, USA, 2013. Available online: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021821s026s031lbl.pdf (accessed on 15 April 2016).
7. Stefani, S., Dowzicky, M.J. Longitudinal assessment of antimicrobial susceptibility among Gram-negative and Gram-positive organisms collected from Italy as part of the Tigecycline Evaluation and Surveillance Trial between 2004 and 2011. Pharmaceuticals 2013, 6, 1381-1406. [CrossRef] [PubMed]
8. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters, version 6.0, European Society of Clinical Microbiology and Infectious Disease: Stockholm, Sweden, 2016, Available online: http://www.eucast.org/clinical_breakpoints/ (accessed on 15 April 2016).
9. Moro, M.L., Marchi, M., Buttazzi, R., Nascetti, S., INF-OSS Project Group. Progress in infection prevention and control in Italy: A nationwide survey. J. Hosp. Infect. 2011, 77, 52-57. [CrossRef] [PubMed]
10. Charrier, L., Argentero, P.A., Farina, E.C., Serra, R., Mana, F., Zotti, C.M. Surveillance of healthcare-associated infections in Piemonte, Italy: Results from a second regional prevalence study. BMC Public Health 2014, 14, 558. [CrossRef] [PubMed]
11. Clinical Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 20th ed., CLSI Supplement M100-S23, CLSI:Wayne, PA, USA, 2013.
12. Clinical Laboratory Standards Institute (CLSI). Development of in Vitro Susceptibility Testing Criteria and Quality Control Parameters, Approved Guideline, 3rd ed., CLSI Document M23-A3, CLSI:Wayne, PA, USA, 2008.
13. European Committee on Antimicrobial Susceptibility Testing. Setting Breakpoints for New Antimicrobial Agents, EUCAST SOP 1.1, 2013. Available online: http://www.eucast.org/documents/sops/ (accessed on 27 October 2016).
14. Marchese, A., Esposito, S., Barbieri, R., Bassetti, M., Debbia, E. Does the adoption of EUCAST susceptibility breakpoints affect the selection of antimicrobials to treat acute community-acquired respiratory tract infections? BMC Infect. Dis. 2012, 12, 181-189. [CrossRef] [PubMed]
15. Hombach, M., Bloemberg, G.V., Böttger, E.C. Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting Gram-negative bacilli. J. Antimicrob. Chemother. 2012, 67, 622-632. [CrossRef] [PubMed]
16. Hombach, M., Böttger, E.C., Roos, M. The critical influence of the intermediate category on interpretation errors in revised EUCAST and CLSI antimicrobial susceptibility testing guidleines. Clin. Microbiol. Infect. 2013, 19, E59-E71. [CrossRef] [PubMed]
17. Jones, R.N., Flonta, M., Gurler, N., Cepparulo, M., Mendes, R.E., Castanheira, M. Resistance surveillance program report for selected European nations (2011). Diagn. Microbiol. Infect. Dis. 2014, 78, 429-436. [CrossRef] [PubMed]
18. Cantón, R., Akóva, M., Carmeli, Y., Giske, C.G., Glupczynski, Y., Gniadkowski, M., Livermore, D.M., Miriagou, V., Naas, T., Rossolini, G.M., et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 2012, 18, 413-431. [CrossRef] [PubMed]
19. Magiorakos, A.P., Suetens, C., Monnet, D.L., Gagliotti, C., Heuer, O.E., EARS-Net Coordination Group and EARS-Net Participants. The rise in carbapenem resistance in Europe: Just the tip of the iceberg? Antimicrob. Resist. Infect. Control 2013, 2, 6. [PubMed]
20. Albiger, B., Glasner, C., Struelens, M.J., Grundmann, H., Monnet, D.L., European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group. Carbapenemase-producing Enterobacteriaceae in Europe: Assessment by national experts from 38 countries, May 2015. Euro Surveill. 2015, 20, 1-18.
21. European Center for Disease Prevention and Control. Carbapenemase-Producing Bacteria in Europe: Interim Results from the European Survey on Carbapenemases-Producing Enterobacteriaceae (EuSCAPE) Project, ECDC: Stockholm, Sweden, 2013.
22. Palacios-Baena, Z.R., Oteo, J., Conejo, C., Larrosa, M.N., Bou, G., Fernández-Martínez, M., González-López, J.J., Martínez-Martínez, L., Merino, M., Pomar, V., et al. Comprehensive clinical and epidemiological assessment of colonization and infection due to carbapenemase-producing Enterobacteriaceae in Spain. J. Infect. 2016, 72, 152-160. [CrossRef] [PubMed]
23. European Center for Disease Prevention and Control. Antimicrobial Resistance Surveillance in Europe 2013, Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net), ECDC: Stockholm, Sweden, 2014.
24. Peleg, A.Y., Seifert, H., Paterson, D.L. Acinetobacter baumannii: Emergence of a successful pathogen. Clin. Microbiol. Rev. 2008, 21, 538-582. [CrossRef] [PubMed]
25. Zavascki, A.P., Carvalhaes, C.G., Picão, R.C., Gales, A.C. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: Resistance mechanisms and implications for therapy. Expert Rev. Anti-Infect. Ther. 2010, 8, 71-93. [CrossRef] [PubMed]
26. Mezzatesta, M.L., Trovato, G., Gona, F., Nicolosi, V.M., Nicolosi, D., Carattoli, A., Fadda, G., Nicoletti, G., Stefani, S. In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy. Ann. Clin. Microbiol. Antimicrob. 2008, 7, 4. [CrossRef] [PubMed]
27. Balode, A., Punda-Polic, V., Dowzicky, M.J. Antimicrobial susceptibility of Gram-negative and Gram-positive bacteria collected from countries in Eastern Europe: Results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010. Int. J. Antimicrob. Agents 2013, 41, 527-535. [CrossRef] [PubMed]
28. Marco, F., Dowzicky, M.J. Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T. E.S.T.) in Spain, 2004-2014. J. Glob. Antimicrob. Resist. 2016, 6, 50-56. [CrossRef] [PubMed]
29. Jones, R.N., Kohno, S., Ono, Y., Ross, J.E., Yanagihara, K. ZAPPS International Surveillance Program (2007) for linezolid resistance: Results from 5591 Gram-positive clinical isolates in 23 countries. Diagn. Microbiol. Infect. Dis. 2009, 64, 191-201. [CrossRef] [PubMed]
30. Sánchez García, M., De la Torre, M.A., Morales, G., Peláez, B., Tolón, M.J., Domingo, S., Candel, F.J., Andrade, R., Arribi, A., García, N., et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010, 303, 2260-2264. [CrossRef] [PubMed]
31. Ross, J.E., Farrell, D.J., Mendes, R.E., Sader, H.S., Jones, R.N. Eight-year (2002-2009) summary of the linezolid (Zyvox® Annual Appraisal of Potency and Spectrum, ZAAPS) program in European countries. J. Chemother. 2011, 23, 71-76. [CrossRef] [PubMed]
32. Limbago, B.M., Kallen, A.J., Zhu, W., Eggers, P., McDougal, L.K., Albrecht, V.S. Report of the 13th vancomycin-resistant Staphylococcus aureus isolate from the United States. J. Clin. Microbiol. 2014, 52, 998-1102. [CrossRef] [PubMed]
33. Melo-Cristino, J., Resina, C., Manuel, V., Lito, L., Ramirez, M. First case of infection with vancomycin-resistant Staphylococcus aureus in Europe. Lancet 2013, 382, 205. [CrossRef]
34. Wang, G., Hindler, J.F., Ward, K.W., Bruckner, D.A. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a University Hospital during a 5-year period. J. Clin. Microbiol. 2006, 44, 3883-3886. [CrossRef] [PubMed]
35. Steinkraus, G., White, R., Friedrich, L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant (MRSA) blood isolates from 2001 to 2005. J. Antimicrob. Chemother. 2007, 60, 788-794. [CrossRef] [PubMed]
36. Sader, H.S., Fey, P.D., Limaye, A.P., Madinger, N., Pankey, G., Rahal, J., Rybak, M.J., Snydman, D.R., Steed, L.L., Waites, K., et al. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob. Agents Chemother. 2009, 53, 4127-4132. [CrossRef] [PubMed]
37. Magiorakos, A.P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M.E., Giske, C.G., Harbarth, S., Hindler, J.F., Kahlmeter, G., Olsson-Liljequist, B., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012, 18, 268-281. [CrossRef] [PubMed]
38. Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, Approved Standard 10th ed., Document MO7-A10, CLSI: Wayne, PA, USA, 2015.
39. Clinical Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 26th ed., CLSI Supplement M100S, CLSI:Wayne, PA, USA, 2016.